Welcome to our dedicated page for RACC news (Ticker: RACC), a resource for investors and traders seeking the latest updates and insights on RACC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RACC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RACC's position in the market.
Research Alliance Corporation III (Nasdaq:RACC) priced its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, for gross proceeds of $75 million. The shares begin trading on the Nasdaq Capital Market on May 20, 2026, with closing expected May 21, 2026.
The SPAC, sponsored by an affiliate of RA Capital Management, aims to pursue a business combination, primarily in healthcare or healthcare-related industries. Leerink Partners is sole bookrunning manager, with participation from multiple institutional investors. The SEC declared the registration statement effective on May 19, 2026.